DEVELOPMENTS IN CORONARY care
specifically aimed at preventing death from arrythmias in acute myocardial infarction (MI) constitute one of the major medical advances of the past decade. The widespread application of constant electrocardiographic monitoring to patients with acute MI has revealed an incidence of arrhythmias previously wholly unsuspected. Indeed, some disturbance of rate, rhythm, or conduction is detected in the vast majority of closely monitored patients within the first week after infarction.1 2, 3 Although arrhythmias in MI can be categorized in many ways, a convenient classification is one which simply divides them into those in which the heart rate is either too slow (bradyarrhythmias) or too fast (tachyarrhythmias). This paper concerns itself with tachyarrhythmias complicating acute MI.
Ectopic tachycardias, whether arising in the atria, atrioventricular (A-V) junction, or ventricles, may precipitate serious and even fatal consequences for the patient in whom they occur. The rapid heart rate often leads to a sharp fall in cardiac output with hypotension and to diminished perfusion of vital organs, one of the most important of which is the heart itself. Similarly, tachycardia may cause congestive failure, particularly when the DESANCTIS ET AL. deleterious effects of the rapid heart rate are superimposed upon a myocardium whose function is already compromised by infarction. The accelerated heart rate increases the demand of the myocardium for oxygen at a time when it can least afford it. Thus, a cardinal role of the coronary care unit is the prevention of tachyarrhythmias and their prompt termination should they occur.
Causes of Tachyarrhythmias
Although much attention has been directed toward the treatment of infarct arrhythmias, considerably less has been paid to those factors which give rise to the disordered rhythms. We would like to consider briefly five broad categories of arrhythmogenic factors in MI: (1) metabolic; (2) anatomic; (3) autonomic; (4) hemodynamic; and (5) iatrogenic.
Metabolic
Metabolic factors are clearly among the most important causes of MI arrhythmias, but precise mechanisms of arrhythmogenesis are imperfectly understood at present. Beck et al. found that arrhythmias in experimental myocardial infarction appeared to arise in the interzone between infarcted and noninfareted myocardium.4 They postulated that the difference in tissue oxygen tensions between ischemic and well-perfused regions of the ventricles created currents leading to ventricular ectopic activity, and consequent ventricular tachycardia or fibrillation. However, a number of subsequent studies designed to test this hypothesis have failed to establish the arrhythmogenic importance of the oxygen differential, and it is likely that this plays little if any role.5
Undoubtedly much more important are the profound mtabolic changes occurring in and around the infarcted myocardium. The death of heart muscle results in a massive escape of intracellular contents into the area of infarction, especially potassium. Harris has shown that this localized hyperkalemia results in a partial depolarization and increased excitability of myocardial cells. He also has postulated that the elevated potassium produces an injury potential that forms currents which extend locally into the region containing the hyperexcitable cells, the summation of these effects combining to produce ectopic ventricular activity.6 In addition to potassium, magnesium moves out of infarcted cells, while sodium and calcium move in. 7 Myocardial necrosis also results in profound localized acidosis as well as release of many other substances into the area of infarction known to have negative inotropic and chronotropic effects, such as adenosine, certain amino acids, and enzymes. 8 How these many disturbances lead ultimately to fatal ventricular fibrillation is also still uncertain. However, the most commonly held theory for the development of fibrillation, either atrial or ventricular, is the "wavelet hypothesis" proposed by Moe.9 According to this theory, fibrillation does not occur in a heart that repolarizes uniformly. However, when there is nonuniformity of recovery of either the atria or the ventricles fibrillation can occur primarily by reentry extension of circulating wavefronts from areas of myocardium still depolarized to zones which have recovered. This effect is further enhanced if nonuniform recovery is combined with inhomogeneous spread of depolarization currents through the heart. Han and colleagues have identified many factors which contribute to nonhomogenous ventricular repolarization such as bradyeardia, sympathetic stimulation, and simple ectopic beats. 12-2 Mandel et al. have demonstrated that ischemia results directly in differences in refractory periods between ischemic and nonischemic tissue.'' Immediately after experimental coronary occlusion, refractory periods in ischemic tissue were shorter than in nonischemic tissue. After 24-72 hours, the refractory periods were significantly longer in the ischemic zones. Once again, this discrepancy in refractory periods could set the stage for the development of reentry tachyeardias.
Active arrhythmias may also be initiated by enhanced automaticity of the specialized cells in the sinoatrial (SA) node, atrium, A-V junction, and ventricular His-Purkinje system which possess pacemaker properties, that is, the ability to depolarize spontaneously in diastole. A number of factors have been identified which increase the rate of spontaneous firing of these cells, including hypoxia, excessive stretch, mechanical trauma, hypercarbia, and acidosis.'4 Furthermore, it has been shown that a weak, constantly applied electric current will increase the slope of phase-4 diastolic depolarization, thereby increasing automaticity.15 Such a current may exist in MI, as noted above.
Recently speculation has arisen that the elevation of free fatty acids noted in the plasma after MI might be related to the induction of ventricular arrhythmias, heart block, and sudden death.16 This The artery to the sinus node arises from the right coronary artery approximately 55% of the time, and from the proximal left circumflex coronary artery 45% of the time. 8 Occlusion of the sinus-node artery can lead to ischemia, and even actual infarction, of this important structure. The result may be instability of the sinus mechanism, even sinus arrest. If bradyeardia occurs, the vulnerability of the atrium to tachyarrhythmias is increased. In addition, the sinus-node artery is usually a major source of blood to the atrial myocardium. Thus, compromise of its flow may result in ischemia or infarction of the atrial musculature, with consequent electrical instability.
The artery to the A-V node arises from the right coronary artery in 90% of human hearts, and from the left circumflex coronary artery 10% of the time (the latter more frequently in men than in women).8 It is usually a distal branch of the major artery supplying the posterior wall of the heart so that heart block is considerably more frequent with inferoposterior infarction than with anterior infarction. Ischemia of this area may enhance automaticity of the A-V junction, leading to junctional tachycardias. Bradycardia from heart block produced by ischemia of the A-V node may also predispose to the development of tachyarrhythmias by contributing to nonuniform repolarization. James has postulated that still another reason for bradycardia in patients with inferoposterior infarction is ischemic stimulation of parasympathetic ganglia and nerve endings which lie in the lower posterior portion of the interatrial septum between the ostium of the coronary sinus and the posterior margin of the A-V node.
Still another potential factor related to tachyarrhythmias is pericarditis. The sinus node is a very superficial structure, and as such is vulnerable to the irritative effects of pericarditis.20 In addition, the atria may be irritated by pericarditis resulting in supraventricular arrhythmias. It 27 They showed that the doses of digitalis glycosides necessary to produce toxic ventricular tachycardia were reduced by approximately one third after infarction. Furthermore, whereas gastrointestinal toxicity was evident before cardiac toxicity in the majority of animals prior to infarction, the converse was true after infarction.
Electrocardiographic Monitoring
At present, primary emphasis in coronary care is placed upon constant monitoring of the electrocardiogram. Marriott and Fogg have emphasized the value of a selective modified precordial electrode (MCL 1) which closely resembles lead V-I, the lead which they consider of greatest value in detecting disturbances of rhythm and conduction. 28 In this system, the positive electrode is positioned in the usual V-I location (fourth right interspace at the right sternal edge), while the negative electrode is positioned just inferior to the outer quarter of the left clavicle. The ground electrode is placed inferior to the right clavicle. This lead system not only provides a more favorable electrocardiogram for monitoring, but removes the electrodes from the areas of primary auscultation on the precordium, permitting easier physical examination.
For the most part, coronary care units rely upon prominent visual display of the electrocardiograms on monitors located at the bedside and throughout the facility. These monitors are randomly viewed by the unit personnel, wvho are also alerted by alarms triggered by the heart rate deviating above or below preset limits. Some units have employed specially trained technicians to observe central banks of monitors. A useful addition to many monitoring systems has been the incorporation of a "memory loop," consisting of a magnetic tape that is constantly recording and erasing the patient ' These instruments monitor the R-R interval of successive beats, and detect shortening from the patient's average R-R interval of more than 20%. 31 The additional incorporation into the system of monitoring for QRS widening adds a further dimension to the usefulness of these systems. Hence, R-R interval and QRS duration can be monitored either separately or in combination, depending on the circumstances. For example, they might be used together for the detection of VPBs in a patient with sinus rhythm and normal QRS width. For the detection of any premature beat (atrial, junctional, or ventricular) or in the presence of bundle-branch block, only the R-R interval might be sensed, whereas monitoring of only the QRS duration might be of value in detecting VPBs in the presence of atrial fibrillation, where the R-R interval of successive beats varies greatly. These instruments can also be programmed to record the number of ventricular premature beats in a given period of time on a simple digital counter, or graphically as a trend recorder, which registers heart rate and frequency of ectopic beats on a slowly moving chart. Computers have also been used to develop histograms of R-R intervals in a variety of forms, showing the scatter of duration of R-R intervals around the usual R-R interval. Such displays have been very useful in assessing the effects of antiarrhythmic agents on an irritable heart.32 Whether these somewhat expensive refinements actually contribute to improved survival in the coronary care unit is still undetermined.
One of the major problems related to computer monitoring of arrhythmias, in addition to the cost, is difficulty in accurately defining P waves. Paroxysmal atrial tachycardia (PAT) is uncommon, occurring in a reported 1-7.5% of patients with MI11 3 In our coronary care unit the incidence is 2%. Episodes may be either short or sustained and are sometimes episodic. Occasionally, the arrhythmia is the result of digitalis toxicity. This should be particularly suspect if PAT in a patient on digitalis is also associated with block. In rare instances, the tachycardia may take the form of a multifocal atrial tachycardia.
When PAT does occur in MI, it is not uncommonly in the setting of pump failure, and its development may result in serious clinical deterioration. Therapy is dictated by the urgency of converting the arrhythmia. In a patient who remains stable during the tachycardia, the usual vagal maneuvers such as carotid sinus pressure and induced gagging may terminate the attack. A Valsalva maneuver is also sometimes effective. In a patient not previously receiving digitalis glycosides, digitalis is frequently successful, particularly if combined with a repeat of vagal maneuvers after administration of the drug. With MI our preference is for a short-acting preparation Onset of atrial fibrillation initiated by an atrial premature beat (lower panel) in a 74-year-old man with an acute diaphragmatic infarct with sinus tachycardia and Wenckebach seconddegree A-V block. The tracing also shows another occasional manifestation of an atrial tachyarrhythmia in the presence of high-grade A-V block, namely, the paradox of slowing of the ventricular rate coincident with onset of the rhythm disturbance. This is presumably the result of concealed conduction of fibrillatory waves, increasing the refractoriness of the A-V junction, which is already slowed in its ability to conduct. fig. 2 ).
Circulation, Volume XLV, March 1972 Atrial flutter may be a very stubborn arrhythmia to treat pharmacologically. It is often difficult to achieve adequate control of the ventricular rate with even large quantities of digitalis. Our approach to the therapy of atrial flutter is generally directed more at terminating the arrhythmia than at controlling the ventricular rate. Assuming that the patient is otherwise stable and not previously receiving digitalis, about half of the usual digitalizing dose of a short-acting glycoside is administered, for example, 0.25 mg of ouabain or 0.5 mg of digoxin. In approximately one fifth of individuals so treated, digitalis alone will terminate the attack. However, if the attack persists more than an hour after digitalis administration, or as initial therapy if the flutter is producing serious compromise of cardiac function, DC cardioversion using a synchronized shock is undertaken. Atrial flutter is extremely responsive to such therapy and can almost invariably be terminated, often with relatively small shocks in the range of 25 to 50 joules. Cardioversion can be performed safely with the small amounts of digitalis recommended above. On rare occasions we have terminated atrial flutter by rapid stimulation of the atrium by way of a transvenous pacing wire.34 This may convert flutter either to sinus rhythm or atrial fibrillation. In the latter case the ventricular rate can be more easily controlled with digitalis if it does not revert spontaneously to sinus rhythm.
If atrial flutter is recurrent and cannot be suppressed, it may become necessary to control the ventricular rate by pushing digitalis. In the absence of left ventricular failure, the addition of propranolol to digitalis may also help control the ventricular rate and may even convert the arrhythmia. Propranolol is usually given in doses of 1-3 mg intravenously every 3-4 hours, or 10-30 mg orally every 4-6 hours.
Atrial Fibrillation
This arrhythmia is about twice as common as atrial flutter in the setting of MI On occasion, in a patient who is stable, an attempt may be made to convert atrial fibrillation with quinidine. However, it is important not to endanger the patient by the administration of large quantities of quinidine, as the arrhythmia is usually easy to convert electrically if it does not convert spontaneously. We usually set 1. gm of quinidine as a maximum total dose to be given in any 24-hour period.
Suippression of Atrial Arrhythmias
As indicated, atrial tachyarrhythmias in MI are frequently recurrent ( fig. 5) . They are usually a phenomenon of the early days of MI and rarely persist after the first week or 10 days. Indeed, it is very rare that an atrial tachyarrhythmia which had its inception during acute MI is present when the patient leaves the hospital. It is generally our policy to place patients who have experienced a supraventricular tachycardia on quinidine. 0.8-1.2 g daily in four divided doses. Alternatively, which fell in this phase, a manifestation to which they gave the name "R on T" phenomenon.39 An example of this is shown in figure 7 . Lown et al. have recently summarized factors important in the genesis of ventricular irritability in MI.25 They point out that it requires extremely high energy levels (in the order of 40,000 gjoules) to produce ventricular fibrillation by stimulating the heart during the vulnerable phase in normal animals. In contrast, only 1 pjoule applied to the endocardium is necessary to produce a ventricular premature beat. iniitiated by ectopic beats outside the vulnerable phase ( fig. 10) .
The generally accepted criteria for the suippression of VPBs in the setting of MI are as follows: (1) when they occur with an absolute frequency of greater than five beats/min; (2) when they fall in the vulnerable phase of the cardiac cycle; (3) when they Figulre 10 Vcnt,ticular tachlycardia inlitiated by a late diastolic envltr iculacr ectopic beat.
are multifocal in origin; and (4) when they are coupled or occur in salvos. On the other hand, discretion should be used in the application of these guidelines. showed that doses above 20 gg/kg/min are usually necessary to achieve an antiarrhythmic effect, whereas doses above 50 ug/kg/min are prone to be associated with toxic side reactions.32 These values correspond to roughly 1-4 mg/min. in an average adult.
Lidocaine has proved to be safe and effective. Side reactions take the form of central nervous system depression or excitation, ranging from obtundation, acute agitation, tinnitus, and visual scintillations to frank seizures. Occasional hypotension and A-V block may occur. However, in general, lidocaine does not alter QRS complexes or P-R or Q-T intervals.
Lidocaine is metabolized rapidly in the liver, its effect lasting for only 15-20 min, but should be used cautiously in the presence of hepatic dysfunction. The short duration of action of lidocaine is advantageous in that any side reactions are quickly dissipated. On the other hand, the short action has the disadvantage that arrhythmias may not be suppressed for long if there is a tendency toward recurrence. The use of intramuscular lidocaine in doses in the range of 300 mg is currently under investigation. 44 This amount has been reported to produce therapeutic levels of lidocaine for periods up to 1 hour.
For patients sensitive to lidocaine or exhibiting persistent ventricular irritability as lidocaine is tapered, one of the longer-lasting antiarrhythmic agents may be used. Our preference is for procainamide, given as a loading dose of 750 mg to 1 g followed by 250 -500 mg every 3-4 hours. Koch-Weser and Circulation, Volume XLV, March 1972 Klein have suggested total doses of 50 mg/kg/day divided into three hourly doses.37 Generally, the drug is administered orally but can be given intramuscularly if necessary. Although procainamide is associated with a high incidence of side reactions when administered over a long period of time,45 side effects with short-term administration are negligible. However, high blood levels may be associated with hypotension and depressed myocardial contractility, especially if some degree of pump failure is already present.
Quinidine in doses of 200-300 mg every 4-6 hours may also be useful in suppressing ventricular irritability. There is one effect of quinidine which must be kept in mind when it is used. Of all of the antiarrhythmic agents, quinidine causes the greatest prolongation of the Q-T interval, and this may pose a potential hazard to patients with ventricular irritability if the irritability is not suppressed. As the Q-T interval lengthens, the T wave-ergo, the vulnerable phase-may be moved into the VPBs, occasionally triggering ventricular tachyarrhythmias. This is very likely the mechanism for the occasional paradoxical increase in ventricular irritability associated with quinidine. The doses of both procainamide and quinidine should be reduced in the presence of hepatic or renal dysfunction.
Diphenylhydantoin has been widely used in the therapy of ventricular irritability, but our experience with it has been rather disappointing, coinciding with that recently reported by Stone et al. 46 However, it does appear to have specific usefulness in arrhythmias due to digitalis toxicity.47 When used to abolish ventricular ectopic beats or ventricular tachycardia, it is usually given intravenously in doses of up to 500 mg at the rate of 100 mg every 5 min. The intravenous preparation is exceedingly caustic and should be introduced through a rapidly running intravenous solution. For continued suppression, diphenylhydantoin is administered orally in doses of 100 mg three or four times daily. Plasma levels of 10-18 mg/liter are usually sufficient to control arrhythmias, and higher levels may be associated with toxic reactions. 48 12 ).56
Not uncommonly, the diagnosis of ventricular tachycardia is more evident at the bedside than on the electrocardiogram. Physical examination may reveal evidence of A-V dissociation. These include (I) intermittent cannon waves in the jugular venous pulses; (2) varying intensity of the first heart sound; (3) variations in systemic peak blood pressure; and (4) extra heart sounds consisting of atrial, ventricular, and summation gallop sounds. All of these signs are the result of random contraction of the atria in relation to the ventricles. 56 Therapy of ventricular tachycardia is dictated largely by the patient's status consequent to the tachycardia. If the arrhythmia is or congestive failure, then intravenous lidocaine can be given as described above. Figure 13 Accelerated idioventricular rhythm complicating acute inferior myocardial infarction. Continuous lead 11. The first two beats in the upper strip are those of normal sinus rhythm at 75 beats/min. In the two panels shown, there are five short runs of accelerated idioventricular rhythm at a rate of 88 beats/min. Routine prophylaxis should not be administered to patients with hypotension, cardiogenic shock, advanced congestive heart failure, or second-or third-degree A-V block. If any prophylactic drug is used, lidocaine given intravenously at doses of 2-3 mg/min for the first 48 hours after MI is probably the simplest and safest.
For almost a decade, the value of so-called "polarizing solution," first introduced by SodiPallares and his associates,65 has been debated. This is a solution consisting of glucose, insulin, and potassium designed to prevent potassium loss from injured myocardial cells. The argument over its efficacy in preventing arrhythmias in MI is still not settled, but the general sentiment in this country based on several negative reports is against its routine use in MI.66
Accelerated Idioventricular Rhythm
This generally benign rhythm has been recognized with increasing frequency in MI. Rothfeld et al. report an incidence of 23% in a series of 300 consecutively monitored patients svith infarction.67 This rhythm occurs as an escape rhythm, usually when sinus bradyeardia is combined with an accelerated ventricular (or junctional) focus, the latter presumably caused by enhanced automaticity as a consequence of the infaret. When the sinus slows, the accelerated rhythm takes over as the dominant cardiac pacemaker, whereas the sinus again captures the ventricles when it speeds up ( fig. 13 ),56 Rarely, the rhythm is seen in atrial fibrillation when there is a slow ventricular response ( fig. 14) .
Rothfeld et al. have described the features of this arrhythmia.68 Because bradyeardia is more common in inferoposterior infaretion, accelerated idioventricular rhythm is more commonly associated with infarets in this location. It is frequently seen during sleep, when the sinus rate slows even more. It begins as an escape rhythm, and fusion beats are common. The rate is usually between 60 and 100 beats/min, occurring usually in brief intermittent salvos of from 4 to 30 beats. It does not adversely affect prognosis, usually disappears spontaneously in 48 hours, and generally does not require treatment.
On the other hand, this arrhythmia does not always occur in pure form. We have seen instances of idioventricular rhythm complicated by premature beats, sometimes apparently from the same focus, sometimes from another focus, degenerating into ventricular tachycardia ( fig. 14) . In such instances, the rhythm should be suppressed. This can often be accomplished simply by accelerating the slow sinus rate with a cardioaccelerator drug such as atropine, or by pacing at a more rapid rate, although the addition of an antiarrhythmic agent may also be necessry.
The Future Challenges
Although much has been accomplished in the past decade in focusing upon the prevention of death from arrythmia in MI, much remains to be done. The basic factors responsible for arrhythmogenesis need further clarification. Better automated systems of monitoring need to be developed, perhaps using simple computers which reliably detect and warn of at least potentially serious arrhythmias. Better antiarrhythmic agents must be found, and the role of cardiac surgery in the therapy of refractory ventricular irritability must be established. A great challenge still unmet is how to prevent those 50% of sudden arrhythmic deaths from coronary disease which occur before patients even arrive at the hospital. Finally, the ultimate treatment of any disease lies in its prevention, and the secrets of how to prevent the development of coronary arteriosclerosis must be solved.
